Adjuvant Pembrolizumab Boosts DFS in High-Risk Muscle Invasive Urothelial Cancer

(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) more than doubled disease-free survival (DFS) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to the AMBASSADOR trial...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news